Anika Therapeutics (ANIK) Operating Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Operating Expenses data on file, last reported at $24.5 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $24.5 million, up 29.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.4 million (up 2.28% YoY), and the FY2025 annual result was $74.9 million, down 7.7% from the prior year.
• Operating Expenses grew to $24.5 million in Q1 2026 per ANIK's latest filing, from $18.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $35.4 million in Q1 2023 and troughed at -$18.9 million in Q4 2023.
• A 5-year average of $19.5 million and a median of $21.5 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses plunged 146.33% in 2022, then jumped 194.2% in 2024.
• A 5-year view of Operating Expenses shows it stood at -$12.6 million in 2022, then slumped by 49.9% to -$18.9 million in 2023, then surged by 194.2% to $17.8 million in 2024, then increased by 3.94% to $18.5 million in 2025, then jumped by 32.12% to $24.5 million in 2026.
• Business Quant data shows ANIK's Operating Expenses at $24.5 million in Q1 2026, $18.5 million in Q4 2025, and $18.8 million in Q3 2025.